2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone
C30H34N6O2 — CID 153081227
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone
2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone (PubChem CID 153081227) has the molecular formula C30H34N6O2 and a molecular weight of 510.64 g/mol. Its IUPAC name is 2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone.
Molecular Properties
| Compound Name | 2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone |
|---|---|
| PubChem CID | 153081227 |
| Molecular Formula | C30H34N6O2 |
| Molecular Weight | 510.64 g/mol |
| Exact Mass | 510.27 |
| IUPAC Name | 2-[6-[1-methyl-5-(piperidin-1-ylmethyl)pyrazol-4-yl]isoquinolin-3-yl]-1-(2-morpholin-4-yl-4-pyridinyl)ethanone |
| SMILES | Cn1ncc(-c2ccc3cnc(CC(=O)c4ccnc(N5CCOCC5)c4)cc3c2)c1CN1CCCCC1 |
| InChI | InChI=1S/C30H34N6O2/c1-34-28(21-35-9-3-2-4-10-35)27(20-33-34)22-5-6-24-19-32-26(16-25(24)15-22)18-29(37)23-7-8-31-30(17-23)36-11-13-38-14-12-36/h5-8,15-17,19-20H,2-4,9-14,18,21H2,1H3 |
| InChIKey | VNHRGYJEUFAZHS-UHFFFAOYSA-N |
| XLogP | 4.28 |
| TPSA | 76.38 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 510.64 |
| LogP ≤ 5 | 4.28 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 153081227 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.